On April 26th, 2024, the Chinese Society of Clinical Oncology (CSCO) Guidelines Conference was held in Jinan. Experts and scholars from various fields of oncology across the country gathered to focus on the latest research progress, discuss clinical practice hotspots, and clarify ideas and directions for the high-quality development of the discipline.

At this conference, CSCO released a total of 32 oncology diagnosis and treatment guidelines, of which 31 were revised and updated editions. The only firstly published one was the Guidelines for Diagnosis and Management of Anti-tumor Drug-induced Liver Injury. This is another drug safety guideline launched by the Antitumor Drug Safety Management Expert Committee of CSCO, following adverse reactions such as thrombocytopenia, anemia, and venous thrombosis related to tumor treatment. It aims to address the risk of drug-induced liver injury (DILI) caused by drug monotherapy and combination therapy in current tumor treatment, enhance physician’ cognition and diagnosis and treatment levels, to improve patients’ quality of life.

Based on solid proof of evidence-based medicine such as registered randomized controlled trials, Bicyclol has been included in the treatment section of the Guidelines for Diagnosis and Management of Anti-tumor Drug-induced Liver Injury, including: “Grade IA Recommendation” for acute liver cell injury or mixed-type DILI patients with significantly elevated ALT; for patients with underlying liver disease, advanced age, previous chemotherapy induced liver injury, and malignant hematological diseases who receive high-dose cytarabine chemotherapy, prophylactic application of Bicyclol can significantly reduce the incidence and severity of DILI, ensuring smooth chemotherapy and good safety.